UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
10.64
-0.07 (-0.65%)
Dec 20, 2024, 4:00 PM EST - Market closed
UroGen Pharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Cash & Equivalents | 124.92 | 95 | 55.41 | 44.36 | 52.86 | 49.69 | Upgrade
|
| Short-Term Investments | 124.66 | 41.97 | 44.56 | 44.78 | 49.15 | 97.39 | Upgrade
|
| Cash & Short-Term Investments | 249.58 | 136.97 | 99.96 | 89.14 | 102.02 | 147.08 | Upgrade
|
| Cash Growth | 69.30% | 37.02% | 12.14% | -12.62% | -30.64% | 45.16% | Upgrade
|
| Receivables | 22.8 | 15.44 | 12.7 | 11.72 | 7.05 | - | Upgrade
|
| Inventory | 7.59 | 5.67 | 4.33 | 4.83 | 1.96 | - | Upgrade
|
| Prepaid Expenses | 14.05 | 10.28 | 11.1 | 7.48 | 3.36 | 1.03 | Upgrade
|
| Restricted Cash | 1.07 | 0.82 | 0.81 | 1.23 | 1.23 | 0.52 | Upgrade
|
| Total Current Assets | 295.1 | 169.19 | 128.91 | 114.39 | 115.62 | 148.63 | Upgrade
|
| Property, Plant & Equipment | 1.66 | 2.36 | 3.75 | 3.15 | 4.2 | 4.71 | Upgrade
|
| Long-Term Investments | 4.64 | 4.5 | - | 0.68 | 1.89 | 48.56 | Upgrade
|
| Other Long-Term Assets | 0.55 | 2.26 | 2.96 | 1.53 | 0.29 | 0.49 | Upgrade
|
| Total Assets | 301.94 | 178.31 | 135.62 | 119.75 | 122.01 | 202.39 | Upgrade
|
| Accounts Payable | 5.56 | 6.51 | 5.53 | 5.79 | 3.27 | 4.69 | Upgrade
|
| Accrued Expenses | 23.16 | 20.84 | 15.11 | 13.26 | 16.31 | 13.2 | Upgrade
|
| Current Portion of Leases | 0.83 | 0.82 | 0.94 | 1.09 | 1.2 | 1.59 | Upgrade
|
| Other Current Liabilities | 3.25 | 3.04 | 2.34 | 2.24 | 0.66 | - | Upgrade
|
| Total Current Liabilities | 32.79 | 31.21 | 23.92 | 22.38 | 21.44 | 19.48 | Upgrade
|
| Long-Term Debt | 121.71 | 98.55 | 97.54 | - | - | - | Upgrade
|
| Long-Term Leases | 0.21 | 0.84 | 1.59 | 0.4 | 1.5 | 2.6 | Upgrade
|
| Other Long-Term Liabilities | 121.72 | 112.92 | 101.94 | 88.56 | 2.72 | - | Upgrade
|
| Total Liabilities | 276.43 | 243.52 | 224.98 | 111.33 | 25.65 | 22.09 | Upgrade
|
| Common Stock | 0.12 | 0.09 | 0.06 | 0.06 | 0.06 | 0.06 | Upgrade
|
| Additional Paid-In Capital | 793.87 | 614.04 | 487.79 | 475.7 | 452.53 | 407.99 | Upgrade
|
| Retained Earnings | -768.71 | -679.35 | -577.1 | -467.32 | -356.5 | -228.02 | Upgrade
|
| Comprehensive Income & Other | 0.24 | 0.01 | -0.11 | -0.03 | 0.27 | 0.28 | Upgrade
|
| Total Common Equity | 25.52 | -65.21 | -89.36 | 8.41 | 96.36 | 180.3 | Upgrade
|
| Shareholders' Equity | 25.52 | -65.21 | -89.36 | 8.41 | 96.36 | 180.3 | Upgrade
|
| Total Liabilities & Equity | 301.94 | 178.31 | 135.62 | 119.75 | 122.01 | 202.39 | Upgrade
|
| Total Debt | 122.75 | 100.21 | 100.06 | 1.49 | 2.7 | 4.19 | Upgrade
|
| Net Cash (Debt) | 131.47 | 41.26 | -0.1 | 88.33 | 101.21 | 191.44 | Upgrade
|
| Net Cash Growth | 145.63% | - | - | -12.73% | -47.13% | 88.95% | Upgrade
|
| Net Cash Per Share | 3.51 | 1.43 | -0.00 | 3.95 | 4.65 | 9.33 | Upgrade
|
| Filing Date Shares Outstanding | 42.2 | 34.12 | 23.44 | 22.67 | 22.27 | 21.15 | Upgrade
|
| Total Common Shares Outstanding | 42.19 | 32.49 | 23.13 | 22.46 | 22.17 | 21.03 | Upgrade
|
| Working Capital | 262.31 | 137.97 | 104.99 | 92.01 | 94.18 | 129.15 | Upgrade
|
| Book Value Per Share | 0.60 | -2.01 | -3.86 | 0.37 | 4.35 | 8.58 | Upgrade
|
| Tangible Book Value | 25.52 | -65.21 | -89.36 | 8.41 | 96.36 | 180.3 | Upgrade
|
| Tangible Book Value Per Share | 0.60 | -2.01 | -3.86 | 0.37 | 4.35 | 8.58 | Upgrade
|
| Machinery | 4.2 | 4.02 | 3.83 | 3.58 | 2.83 | 1.45 | Upgrade
|
| Leasehold Improvements | 0.62 | 0.62 | 0.62 | 0.62 | 0.61 | 0.53 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.